infusion therapy News
-
Fresenius Kabi Completes Acquisition of Ivenix
Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers healthcare professionals a broad and expanding portfolio of advanced infusion pumps and solutions to meet health care needs across the continuum of care. Fresenius Kabi is the leading provider of IV pumps and solutions in Europe. The company is now investing to ...
By Ivenix, Inc.
-
Velano’s Vascular Access Technologies Help Hospitals Meet 2021 Infusion Therapy Standards of Practice
Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. Updated every five years and considered the preeminent guidance for infusion therapy, the newly reset standards from the Infusion Nurses ...
-
Velano’s Vascular Access Technologies Help Hospitals Meet 2021 Infusion Therapy Standards of Practice
SAN FRANCISCO, January 25, 2021 — Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. Updated every five years and considered the preeminent guidance for infusion therapy, the newly reset ...
-
Christie Medical Holdings, Inc., & B. Braun Medical Announce Collaboration Aimed at Improving Peripheral IV Access Success
Christie® Medical Holdings, Inc., with its market-leading vein finder technology, VeinViewer® system, today announced an alliance with B. Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. Many ...
-
Inspiration Healthcare Group PLC New Head Office Opened by Local MP
Inspiration Healthcare Group plc is pleased to announce the opening of its new corporate head office in the Manor Royal Business District, Crawley, UK. The newly redeveloped 4,500 ft2 office in the Satellite Business Village was officially opened on Friday 3rd March 2017 by Henry Smith MP who unveiled a commemorative plaque and joined guests, the Inspiration Healthcare Group plc Board of ...
-
Hunterdon Healthcare Patients Benefit From Veinviewer To Reduce Sticks And PICCs
Hunterdon Medical Center, a 178-bed non-profit community hospital, and Christie Medical Holdings, Inc., a global leader in portable vein finders, today announced that use of the Christie VeinViewer® Vision2 is helping to improve the level of care provided to their patients. “A key goal for implementation of VeinViewer systems was to decrease the number of central lines placed in favor ...
-
GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and ...
-
Deborah Heart and Lung Center Introduces the Ivenix Infusion System to the Hospital
Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system. “Though everyone is familiar with IV pump delivery systems used to administer medications during a patient’s hospital stay, improvements in technology have allowed us to do it in a controlled and measured way,” said Rita Zenna, RN, Deborah’s Vice ...
By Ivenix, Inc.
-
Immunai Raises $60M to Reprogram Immunity
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...
By Immunai
-
Oncodisc Inc. Acquired by PAVmed Digital Health Company Veris Health Inc.
WALNUT CREEK, Calif., June 2, 2021 /PRNewswire/ -- Oncodisc Inc. ("Oncodisc") today announced that it was acquired by Veris Health Inc ("Veris"), a majority owned digital health subsidiary of PAVmed Inc. ("PAVmed"). Oncodisc, a digital health company with groundbreaking tools to improve personalized cancer care through remote patient monitoring, was founded by experienced ...
By Oncodisc
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update. “After a busy 2021 with new patients dosed across three clinical trials, we acted in early January to strategically position AVROBIO ...
-
Flowonix Receives FDA Approval to Market Prometra II Pump for use with Intrathecal Baclofen
Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen. Flowonix introduced the Prometra II 40mL pump to the US market in November 2019, providing patients and clinicians a choice between 20 mL and 40 mL capacities when choosing an intrathecal pump delivery device. The ...
-
Flowonix Receives FDA Approval for Software Upgrade Designed to Improve User Experience
Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Flowonix Maestro™ Software for Clinician Programmers used to program Prometra® Pump Systems. The new software is designed to improve the user experience for both clinicians and patients. Flowonix expects to begin introducing the new software to customers and implementing the ...
-
Bexson Biomedical Hires Veteran Medical Device Development Leader, Will Focus On New Dosing & Delivery Solutions For Controlled Substances
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its senior leadership team. As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable ...
-
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...
-
Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy
Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. "The study ...
-
Flowonix Medical Inc. And Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you